Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Vicuron to amend anidulafungin NDA

Vicuron (MICU; NMerc:MICU) said it will amend its NDA for anidulafungin to treat

Read the full 139 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE